John J. V

Nov 8, 2024 | academic.oup.com | Novartis Campus |John J. V |Baylor Heart |East Hannover

Heart failure (HF) outcomes reported by investigators in cardiovascular (CV) outcome trials are commonly referred for centralized adjudication by a blinded committee of clinical experts to select relevant clinical endpoints for analysis.1 This process has been encouraged by regulators on the premise that standardization of endpoint ascertainment through centralized review will both enhance the face validity of trial results and reduce bias by filtering the ‘noise’ of spurious events that...

Nov 30, 2023 | eprints.gla.ac.uk | Joao Pedro |John F |John J. V |Carolyn S P

Monzo, L. et al. (2023) High risk of stroke in patients with worsening heart failure, reduced ejection fraction, coronary heart disease and sinus rhythm: risk prediction score analysis from the COMMANDER-HF trial. Journal of Cardiac Failure, (Accepted for Publication)Text310206.pdf - Accepted Version Restricted to Repository staff only Available under License Creative Commons Attribution Non-commercial No Derivatives.

Sep 12, 2023 | eprints.gla.ac.uk | Carolyn S.P |De Boer |Anna Maria |John J. V

Peikert, A. et al. (2023) Contemporary use and implications of beta-blockers in patients with HFmrEF orHFpEF: the DELIVER Trial. JACC: Heart Failure, (Accepted for Publication)Text306768.pdf - Accepted Version Restricted to Repository staff only1MBItem Type:ArticlesAdditional Information:The DELIVER trial was funded by Astra Zeneca.

Sep 5, 2023 | eprints.gla.ac.uk | Freny Vaghaiwalla |John J. V

Wang, X. et al. (2023) Sex differences in clinical characteristics and outcomes after myocardial infarction with low ejection fraction: insights from PARADISE‐MI. Journal of the American Heart Association, 12(17), e028942. (doi: 10.1161/JAHA.122.028942) (PMID:37609931) (PMCID:PMC10547323) Text310321.pdf - Published Version Available under License Creative Commons Attribution Non-commercial No Derivatives.

Aug 14, 2023 | eprints.gla.ac.uk | Hiddo J. L |John J. V

Heerspink, H. J. L. et al. (2023) Estimated lifetime benefit of novel pharmacological therapies in patients with type 2 diabetes and chronic kidney disease: a joint analysis of randomized controlled clinical trials. Diabetes, Obesity and Metabolism, 25(11), pp. 3327-3336. (doi: 10.1111/dom.15232) (PMID:37580309) Text312372.pdf - Published Version Available under License Creative Commons Attribution Non-commercial.